Boron Neutron Capture Therapy Toward Clinical Trials of Glioma Treatment

Opening Speech; E.D. Hondros. Welcome Address; H.H. van der Kroonenberg. Safety and Efficacy in Boron Neutron Capture Therapy; D. Gabel. Some Aspects of BNCT at the Brookhaven National Laboratory; D.D. Joel, et al. INEL BNCT Program Directions with Respect to Clinical Trials of BNCT; R.V. Dorn III. The Department of Energy Research Program in Boron Neutron Capture Therapy; R.W. Wood, D.W. Cole Jr. Current Overview on the Approach of Clinical Trials at Petten; R.L. Moss. Review of the Physics Calculations Performed for the BNCT Facility at the HFR Petten; P. Watkins, et al. From Filter Installation to Beam Characterization; F. Stecher-Rasmussen, et al. Neutron Spectrometry Measurements of the Petten HFR, HB11 Neutron Beam; C.A. Perks, H.J. Delafield. A Semi-Empirical Method of Treatment Planning for Boron Neutron Capture Therapy; C.P.J. Raaijmakers, et al. Present Status of the Three-Dimensional Treatment Planning Methodologies for the Petten BNCT Facility; P. Watkins. A Phase 1 Biodistribution study of p-Boronophenylalanine; J.A. Coderre. RBE in Normal Tissue Studies; R.A. Gahbauer, et al. Treatment planning and optimization for Pion Therapy; H. Blattmann. Dose Calculations Based on Images Reconstructions; F.J. Wheeler, D.E. Wessol. Borocaptate Sodium (BSH) Pharmacokinetics in Glioma Patients; H. Fankhauser, et al. BSH in Patiens with Malignant Glioma: Distribution in Tissue, Comparison between BSH Concentration and Histology; D. Haritz, et al. Macroscopic and Microscopic Biodistribution of BSH in a Rat Glioma Model; C.P. Ceberg, et al. Healthy Tissue Tolerance Studies for BNCT at the High Flux Reactor in Petten-First Results; A. Siefert. Cellular Pharmacokinetics of BNCT Compounds and their Cellular Localization with EELS/ESI; R. Verrijk, et al. Large Animal Model Studies of Normal Tissue Tolerance using an Epithermal Neutron Beam and Borocaptate Sodium; P.R. Gavin, et al. Proposal for Patient Selection Criteria and Follow-up for BNCT in Patients with Supratentorial Malignant Gliomas; H. Fankhauser, G. Stragliotto. A Proposal for Phase 1 Clinical Trials of Glioma Patients; H. Bartelink. Approaches to the Design and Evaluation of Compound for BNCT; A.H. Soloway, et al. The implementation Strategy for BNCT Trials in Australia; B.J. Allen. Author Index. Participants. Subject Index. [End of file]